Monroeville, Pennsylvania Clinical Trials

A listing of Monroeville, Pennsylvania clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 515 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

UPMC Hillman Cancer Ctr /ID# 230731
 (9.1 away) Contact site
  • 254 views
  • 29 Apr, 2021
  • +134 other locations
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

UPMC Hillman Cancer Ctr /ID# 218134
 (9.1 away) Contact site
  • 39 views
  • 29 Apr, 2021
  • +148 other locations
featured
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

solid tumors
cancer
UPMC CANCER CENTER
 (9.0 away) Contact site
  • 25 views
  • 14 Dec, 2020
  • +8 other locations
featured
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

graft-versus-host disease
UPMC Hillman Cancer Center
 (9.0 away) Contact site
  • 1462 views
  • 08 Dec, 2020
  • +10 other locations
featured
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).  

metastatic merkel cell carcinoma
merkel cell carcinoma
carcinoma
metastatic cancer
measurable disease
UPMC CANCERCENTER
 (9.6 away) Contact site
  • 101 views
  • 14 Dec, 2020
  • +6 other locations
featured
Arise 2 - A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.  

hypersomnia
Consolidated Clinical Trials
 (8.1 away) Contact site
  • 607 views
  • 23 Nov, 2020
  • +17 other locations
featured
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).  

lymphoma
lymphomas
b-cell lymphoma
WESTERN PENNSYLVANIA HOSPITAL
 (9.9 away) Contact site
  • 45 views
  • 14 Dec, 2020
  • +4 other locations
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

adjuvant chemotherapy
renal function
erdafitinib
dose regimen
measurable disease
University of Pittsburgh Medical Center (UPMC)
 (9.0 away) Contact site
  • 40 views
  • 28 Jul, 2021
  • +152 other locations
Study of Octaplex a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to that Beriplex P/N (Kcentra).

Octapharma Research Site
 (9.0 away) Contact site
  • 0 views
  • 01 Aug, 2021
  • +76 other locations
A Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of JNJ-63723283 an Anti-PD-1 Monoclonal Antibody in Participants With Advanced Cancers

The Primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, …

primary cancer
lung cancer
monoclonal antibodies
UPMC Cancer Centers
 (9.0 away) Contact site
  • 48 views
  • 22 Jul, 2021
  • +34 other locations